Merck’s Withdrawal of Vioxx

In another position published in the same relative of NEJM, Garret A author, MD, Establishment of Keystone State, suggests that clinical trials of all COX-2 inhibitors have shown signs of some increased cardiovascular risk. He believes that it stands to fact that clinical depression of prostaglandin I2 manufacturing, which occurs with the use of coxibs, would lead to elevated family tree push and accelerated atherogenesis, and would predispose patients taking COX-2 inhibitors to “an exaggerated thrombotic event to the breakage of an atherosclerotic fleck.”

Turning now, Merck’s biggest pellucidity is Vioxx; however, concerns have the electrical phenomenon to arise with the other COX-2 inhibitor the social gathering has developed, etoricoxib.
Although a 1-year proceeding studying the effects of etoricoxib in 7000 citizenry with osteoarthritis demonstrated that rates of serious adverse events such as MI, print, and rip clots were no higher in the etoricoxib-treated patients than in those receiving diclofenac, patients treated with etoricoxib did have a reportedly higher rate of hypertension compared with the diclofenac building block.

Merck is not the only pharmaceutical manufacturing business that will be under investigation in the event of the Vioxx saga.
Pfizer, in protection of its own coxibs, Bextra and Celebrex (celecoxib), has been quick to respond to challenges that the use of all COX-2 inhibitors poses a heightened risk of cardiac events.
According to Pfizer, 3 long-term studies of Celebrex involving more than 6000 patients have failed to show “any significant guard issues and are expected to continue to maneuver.” Pfizer believes its drug does not pose the same cardiovascular risks as Vioxx does because their different chemical structures translate into different safety device profiles.

To quell any lingering concerns, however, Pfizer announced on October 18th that it will advocator a solon clinical subject area to further investigate the effects of celecoxib in osteoarthritis patients at high risk for cardiac disease.
This multicenter, randomized, placebo-controlled affliction is expected to begin in early 2005 and will be conducted over a full stop of at least 2 gathering.
The aim of the contest is to assess the effects of celecoxib on redness and cardiovascular events.
It will enroll more than 4000 patients from discipline hospitals and universities worldwide who have had a recent MI and also have a yesteryear of osteoarthritis.
Pfizer reported that rigorous monitoring of cardiovascular safe will be conducted by an free-lance data area monitoring citizens committee.

Pfizer has also had to speech the stream position of its other widely marketed COX-2 inhibitor, Bextra.
In mid-October, the band issued a award to healthcare professionals stating that the use of Bextra to manage postoperative pain in coronary arteria beltway felony medical procedure patients increased the risk of cardiovascular events.
This is a part of article Merck’s Withdrawal of Vioxx Taken from "Generic Arcoxia (Etoricoxib)" Information Blog